27th week of 2022 patent applcation highlights part 22 |
Patent application number | Title | Published |
20220213069 | ANTAGONISTS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M4 - Disclosed herein are substituted hexahydro-1H-cyclopenta[c]pyrrole compounds, which may be useful as antagonists of the muscarinic acetylcholine receptor M | 2022-07-07 |
20220213070 | COMPOUNDS INHIBITING TDG ACTIVITY - The present invention provides a class of compounds inhibiting TDG activity. Specifically, the present invention provides a compound having a novel structure as shown in formula I. The small molecule inhibitor of the present invention has an excellent inhibitory effect on TDG. | 2022-07-07 |
20220213071 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASE - The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. | 2022-07-07 |
20220213072 | METABOLITES OF GLP1R AGONISTS - The present invention provides compounds of Formula XA-1, XA-2, XA-3, XA-4, XA-5, or XA-6, or metabolites of Compound 1 or metabolites of a compound of Formula I, PA-I, or PA-III, including compositions and salts thereof, which are useful in the prevention and/or treatment of a disease or disorder such as T2DM, obesity, or NASH, as well as analytical methods related to the administration of Compound 1 or a compound of Formula I, PA-1, or PA-III. | 2022-07-07 |
20220213073 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF FUNGAL INFECTIONS - The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX or Formula X and, the methods for the treatment of fungal infections may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of fungal infections. | 2022-07-07 |
20220213074 | ABHD12 INHIBITORS AND METHODS OF MAKING AND USING SAME - Provided herein are compounds and compositions useful as modulators of ABHD12. Furthermore, the subject compounds and compositions are useful as immunotherapies in treating, for instance, cancer or infectious diseases. | 2022-07-07 |
20220213075 | 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF - A 3-aryloxyl-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof are provided. Specifically, a compound, or a pharmaceutically acceptable salt or a prodrug thereof, the compound having a structure of formula I is described. The compound, or pharmaceutically acceptable salt or prodrug thereof has an excellent inhibition function for a transient receptor potential channel protein (TPR), and has a good treatment function for diseases associated with the TPR. | 2022-07-07 |
20220213076 | GHRELIN O-ACYLTRANSFERASE INHIBITORS - This invention relates to novel compounds according to Formula (I) which are inhibitors of ghrelin O-acyltransferase (GOAT), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of metabolic disorders (e.g. Prader-Willi syndrome, metabolic syndrome, insulin resistance, impaired glucose tolerance, prediabetes, diabetes mellitus (e.g., type II diabetes mellitus), dysglycemia (e.g., hyperglycemia), obesity (e.g., obesity caused by Prader-Willi syndrome), increased adiposity, poor glycemic control, hyperphagia, impaired satiety, dyslipidemia (e.g., atherogenic dyslipidemia), hepatic steatosis (e.g., non-alcoholic fatty liver disease (e.g., non-alcoholic steatohepatitis))), psychiatric disorders (e.g., eating disorders (e.g., bulimia nervosa, binge eating disorder, night-time eating syndrome), substance related disorders (e.g., addiction disorders (e.g., alcohol, smoking, overeating, or use of illicit drugs))), as well as disorders related to or complications of metabolic or psychiatric disorders (e.g., cardiovascular diseases (e.g., diabetic heart disease (e.g., diabetic cardiomyopathy), heart failure, or hypertension), ischemia (e.g., myocardial ischemia, cerebral ischemia, ischemic stroke), or BMI-related cancers (e.g., pancreatic cancer, gallbladder cancer, esophageal cancer, colorectal cancer, breast cancer etc.). | 2022-07-07 |
20220213077 | INHIBITORS FOR PROGRAMMED CELL NECROSIS AND PREPARATION METHOD THEREFOR AND USE THEREOF - Provided in the present invention are inhibitors for programmed cell necrosis, a preparation method therefor and a use thereof. Specifically, provided in the present invention are a compound represented by formula I and a composition comprising same. The described compound may be used to prepare a pharmaceutical composition for the prevention and/or treatment of diseases involving cell death and/or inflammation. | 2022-07-07 |
20220213078 | MODULATORS OF THE INTEGRATED STRESS RESPONSE PATHWAY - The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts, solvates, hydrates, tautomers or stereoisomers thereof, wherein R | 2022-07-07 |
20220213079 | ALIPHATIC ACID AMIDE DERIVATIVE - The present invention relates to a compound represented by formula (1): | 2022-07-07 |
20220213080 | PIPERLONGUMINE-BASED COMPOUND AND IMMUNO REGULATOR COMPRISING THE SAME - Disclosed are a novel piperlongumine-based compound, an immuno regulator containing as an active ingredient the compound, or a pharmaceutically acceptable salt or solvate thereof, and a health functional food for immune regulation. | 2022-07-07 |
20220213081 | GEM-DISUBSTITUTED PYRROLIDINES, PIPERAZINES, AND DIAZEPANES, AND COMPOSITIONS AND METHODS OF MAKING THE SAME - Described here are transition metal-catalyzed enantioselective arylation and vinylation reactions of α-substituted lactams, such as γ-lactams. The use of various electrophiles and ligands are described, and result in the construction of α-quaternary centers in good yields (up to 91% yield) and high enantioselectivities (up to 97% ee). | 2022-07-07 |
20220213082 | PRODRUG OF CASPASE INHIBITOR - The present invention relates to a lactone moiety-bearing isooxazoline derivative, which is a prodrug of a caspase inhibitor, and a pharmaceutical composition comprising same. | 2022-07-07 |
20220213083 | FXR SMALL MOLECULE AGONIST AND PREPARATION METHOD THEREFOR AND USE THEREOF - An FXR small molecule agonist and a preparation method therefor and a use thereof, having a structure as shown in formula (I). The compound represented by formula (I) has FXR agonistic activity and is capable of preparing drugs for treatment of FXR-related diseases. | 2022-07-07 |
20220213084 | 1,3,4-OXADIAZOLE DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS - The present invention refers to oxadiazole compounds suitable as HDAC6 inhibitors. Processes for their preparation and their medical uses in treating HDAC6-related diseases or disorders are also disclosed. | 2022-07-07 |
20220213085 | COMPOUND CONTAINING FUSED RING, USE THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING SAME - Disclosed are a compound containing a fused ring, a use thereof and a pharmaceutical composition containing same. Provided are a compound as shown in formula I-A, a pharmaceutically acceptable salt thereof, a solvate thereof, a solvate of the pharmaceutically acceptable salt thereof or a crystal form thereof. The compound can significantly reduce the levels of HBsAg, HBeAg and HBV DNA, and can be used for preparing a drug for treating hepatitis B, and has good market prospects. (I-A) | 2022-07-07 |
20220213086 | AZOLE COMPOUNDS AS IRAK INHIBITORS, PREPARATION METHODS AND MEDICINAL USES THEREOF - This application discloses azole compounds of formula (I) useful as IRAK inhibitors and therapeutic agents for treatment of IRAK, especially IRAK-4, mediated disease or disorders, including autoimmune diseases, cancers, neurodegenerative disorders, viral diseases, and inflammatory disorders, hereditary disorders, and so on. The application also discloses pharmaceutical compositions containing these compounds, as well as synthetic methods and medical uses of the compounds. | 2022-07-07 |
20220213087 | ASPARAGINE ENDOPEPTIDASE (AEP) INHIBITORS, COMPOSITIONS, AND USES RELATED THERETO - This disclosure relates to asparagine endopeptidase inhibitors and compositions and uses related thereto. In certain embodiments, the asparagine endopeptidase inhibitors are useful for improving memory, treating or preventing cancer, neurodegenerative diseases, and cognitive disorders. In certain embodiments, the disclosure relates to pharmaceutical compositions comprising an asparagine endopeptidase inhibitor and a pharmaceutically acceptable excipient. | 2022-07-07 |
20220213088 | INHIBITING USP36 - The present disclosure is directed to compounds of formulas (I)-(VI), which are useful as modulators of USP36. The compounds are further useful in the inhibition of USP36 and the treatment of diseases or disorders associated with the inhibition of USP36. For instance, the disclosure is concerned with compounds and compositions for inhibition of USP36, methods of treating diseases associated with the inhibition of USP36 (e.g., certain forms of cancer), and methods of synthesis of these compounds. | 2022-07-07 |
20220213089 | INHIBITING CYCLIC AMP-RESPONSIVE ELEMENT-BINDING PROTEIN (CREB) - The present disclosure is directed to inhibitors of the CBP/p300 family of bromodomains. The compounds can be useful in the treatment of disease or disorders associated with the inhibition of the CBP/p300 family of bromodomains. For instance, the disclosure is concerned with compounds and compositions for inhibition of the CBP/p300 family of bromodomains, methods of treating diseases or disorders associated with the inhibition of CBP/p300 family of bromodomains (e.g., certain forms of cancer), and methods of synthesis of these compounds. | 2022-07-07 |
20220213090 | HETEROCYCLIC COMPOUNDS AS IMMUNOMODULATORS - Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections. | 2022-07-07 |
20220213091 | SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS - The present disclosure relates generally to certain 6-azabenzimidazole compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of diseases, disorders, or infections modifiable by hematopoietic progenitor kinase 1 (HPK1) inhibitors, such as HBV, HIV, cancer, and/or a hyper-proliferative disease. | 2022-07-07 |
20220213092 | BICYCLIC PYRAZOLE BRUTON'S TYROSINE KINASE INHIBITORS - The present invention provides for compounds of formula (I) | 2022-07-07 |
20220213093 | HETEROCYCLIC MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS - The invention provides new heterocyclic compounds having the general formula (I) | 2022-07-07 |
20220213094 | Substituted Imidazo[l,2-a]-pyridines as IRAK 1/4 and FLT3 Inhibitors - Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer or blood disorders). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein. | 2022-07-07 |
20220213095 | P2X7 MODULATORS - The present invention is directed to compounds of Formulas (I, IIa and IIb): | 2022-07-07 |
20220213096 | PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS - The present disclosure provides selective phosphoinositide 3-kinase gamma inhibitors of Formula (I) including (I-a), (I-b), (I-c), and (I-d), or pharmaceutically acceptable salts thereof. These compounds are useful for the treatment of conditions mediated by one or more PI3K isoforms, such as PI3K gamma (PI3Kγ). The present disclosure further provides methods of inhibiting phosphoinositide 3-kinase gamma using these compounds for treatment of disorders related to phosphatidylinositol 3-kinase gamma activity. | 2022-07-07 |
20220213097 | NAPHTHYRIDINE DERIVATIVES AS PRC2 INHIBITORS - Disclosed are compounds of formula (I) or (II) that inhibit Polycomb Repressive Complex 2 (PRC2) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention. | 2022-07-07 |
20220213098 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE COMPRISING SAME - The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same. | 2022-07-07 |
20220213099 | PRODRUG COMPOUNDS - Disclosed are compounds of Formula (I), Formula (II), Formula (III), and Formula (IV): or salts thereof, wherein R | 2022-07-07 |
20220213100 | NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE REGULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Disclosed are a nitrogen-containing heterocyclic derivative regulator, a preparation method therefor and an application thereof. In particular, disclosed are a compound as represented by general formula (I), a preparation method for the compound and a pharmaceutical composition containing the compound, and the use thereof as a KRAS G12C mutation inhibitor in treatment of diseases or symptoms such as leukemia, neuroblastoma, melanoma, breast cancer, lung cancer and colon cancer, wherein the definitions of substituents in general formula (I) are the same as those in the description. | 2022-07-07 |
20220213101 | INHIBITORS OF KRAS G12C AND METHODS OF USING THE SAME - Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers. | 2022-07-07 |
20220213102 | DIAZEPINONE DERIVATIVES AS CAPSID ASSEMBLY MODULATORS - Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the HBV CAM. Such compounds are represented by Formula (I) as follows: | 2022-07-07 |
20220213103 | 9H-PYRROLO-DIPYRIDINE DERIVATIVES - The invention relates to 9H-pyrrolo-dipyridine derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as radiopharmaceuticals in particular as imaging agents for the detection of Tau aggregates. | 2022-07-07 |
20220213104 | METHOD FOR PRODUCING CYCLIC IMIDE COMPOUND, COMPOSITION, AND COMPOUND - A first object of the present invention is to provide a method for producing a cyclic imide compound with high yield and high purity. A second object of the present invention is to provide a composition that can be used in the method for producing a cyclic imide compound with high yield and high purity. A third object of the present invention is to provide an intermediate compound that can be used in the method for producing a cyclic imide compound with high yield and high purity. The method for producing a cyclic imide compound according to the present invention includes reacting a compound represented by formula (1) below with at least one amine compound to obtain a compound represented by formula (2) below. | 2022-07-07 |
20220213105 | PROCESS FOR PREPARING ENANTIOMERICALLY ENRICHED JAK INHIBITORS - Improved processes and intermediates for preparing ruxolitinib and deuterated analogs of ruxolitinib are disclosed. | 2022-07-07 |
20220213106 | Inhibitors of Bruton's Tyrosine Kinase - Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate irreversible inhibitor of a protein, including a kinase. | 2022-07-07 |
20220213107 | TERTIARY ALCOHOLS AS PI3K-y INHIBITORS - This application relates to compounds of Formula (I): | 2022-07-07 |
20220213108 | DEAZAGUAINE COMPOUNDS AS JAK2 V617F INHIBITORS - The present application provides deazaguaine compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer. | 2022-07-07 |
20220213109 | KRAS mutant protein inhibitors - The invention relates to a KRAS mutant protein inhibitor shown as formula (I), a composition containing the inhibitor and the use thereof. | 2022-07-07 |
20220213110 | COMPOUND AND PRODUCTION METHOD THEREOF, AFX-TYPE ZEOLITE AND PRODUCTION METHOD THEREOF, AND HONEYCOMB STACKED CATALYST - The present invention provides, for example, a compound represented by formula (1), or a salt thereof: | 2022-07-07 |
20220213111 | SUBSTITUTED HETEROCYCLES AS CYCLIC TREX1 INHIBITORS - The present invention provides compounds of Formula I: | 2022-07-07 |
20220213112 | PYRROLE TRICYCLIC COMPOUNDS AS A2A / A2B INHIBITORS - This application relates to compounds of Formula (I): | 2022-07-07 |
20220213113 | NITROGEN-CONTAINING CONDENSED CYCLIC COMPOUNDS, FLUORESCENCE EMITTERS, ORGANIC ELECTROLUMINESCENT DEVICES, AND MATERIALS FOR ORGANIC ELECTROLUMINESCENT DEVICES - The present disclosure relates to a nitrogen-containing condensed cyclic compound having a particular structure and satisfying a particular condition. The present disclosure also relates to a fluorescence emitter that includes the nitrogen-containing condensed cyclic compound having a particular structure and is used together with a phosphorescent complex. In addition, the present disclosure relates to a material for the organic electroluminescent device, including the nitrogen-containing condensed cyclic compound having a particular structure and a phosphorescent complex. Moreover, the present disclosure relates to an organic electroluminescent device including the nitrogen-containing condensed cyclic compound, the fluorescence emitter, and the material for an organic electroluminescent device. | 2022-07-07 |
20220213114 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES - Pyranoyrazoles and pyrazolopyridines of formula I or formula II are disclosed: | 2022-07-07 |
20220213115 | SUBSTITUTED 1-OXO-ISOINDOLINE-5-CARBOXAMIDE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure: | 2022-07-07 |
20220213116 | ORGANIC ELECTROLUMINESCENT MATERIAL AND DEVICE THEREOF - Provided are an organic electroluminescent material and device. The organic electroluminescent material is a compound having a structure of Formula 1. Those novel compounds are applicable to electroluminescent devices and can provide better device performance, such as an increase in device lifetime. Further provided are an electroluminescent device containing the compound and a compound composition containing the compound. | 2022-07-07 |
20220213117 | PRODRUGS OF MODULATORS OF THE NMDA RECEPTOR - The present invention is directed to novel prodrugs of modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression. | 2022-07-07 |
20220213118 | UBIQUITIN-SPECIFIC PROTEASE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOFF - A compound represented by formula I and a racemate, a stereoisomer, a tautomer, an isotopic marker, nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, a pharmaceutically acceptable salt or a prodrug thereof, a pharmaceutical composition comprising same, a preparation method therefor, and a pharmaceutical use thereof are described. The compound has the activity of inhibiting USP28 and/or USP25. The structure of the formula I is as follows. | 2022-07-07 |
20220213119 | THIENOHETEROCYCLIC DERIVATIVE, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF - Provided are a thienoheterocyclic derivative, a preparation method therefor and the medical use thereof. In particular, provided are a thienoheterocyclic derivative represented by formula (I), a preparation method therefor, a pharmaceutical composition containing the derivative, the use of same as a therapeutic agent, particularly as an ERK inhibitor, and the use of same in the preparation of a drug for treating or preventing cancers, inflammation or other proliferative diseases, wherein each substituent of formula (I) is the same as defined in the description. | 2022-07-07 |
20220213120 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME - The present specification relates to a heterocyclic compound represented by Chemical Formula 1, and an organic light emitting device comprising the same. | 2022-07-07 |
20220213121 | SUBSTITUTED 1,2,3,3a,4,5,7,9,13,13a-DECAHYDROPYRIDO[1',2':4,5]PYRAZINO[1,2-a]PYRROLO[- 1,2-c]PYRIMIDINES HAVING HIV INTEGRASE INHIBITORY ACTIVITY - Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1′,2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having the anti-virus activity, particularly the HIV integrase inhibitory activity, and a pharmaceutical composition containing the same, particularly an anti-HIV pharmaceutical composition. | 2022-07-07 |
20220213122 | SUBSTITUTED 1,6-DIHYDROPYRIDINONES AND 1,2-DIHYDROISOQUINOLINONES AS BET INHIBITORS - Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided. | 2022-07-07 |
20220213123 | THIENOPYRIDINONE COMPOUNDS - The invention relates to new thienopyridinone compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as FGFR (fibroblast growth factor receptor) inhibitors and to their use in the treatment of diseases, e.g. cancer. | 2022-07-07 |
20220213124 | NITROGEN-CONTAINING COMPOUND, ELECTRONIC ELEMENT, AND ELECTRONIC DEVICE - Provided are a nitrogen-containing compound, an electronic element, and an electronic device, and relates to the technical field of organic materials. The nitrogen-containing compound is shown as formula I, and can reduce the working voltage of an electronic element, improve the efficiency of an OLED, and prolong the service life of an OLED. | 2022-07-07 |
20220213125 | Extruded Metal-organic Framework Materials and Methods For Production Thereof - Metal-organic frameworks (MOFs) are highly porous entities comprising a multidentate ligand coordinated to multiple metal atoms, typically as a coordination polymer. MOFs are usually produced in powder form. Extrusion of powder-form MOFs to produce shaped bodies has heretofore proven difficult due to loss of surface area and poor crush strength of MOF extrudates, in addition to phase transformations occurring during extrusion. The choice of mixing conditions and the mixing solvent when forming MOF extrudates can impact these factors. Extrudates comprising a MOF consolidated material may feature the MOF consolidated material having a BET surface area of about 50% or greater relative to that of a pre-crystallized MOF powder material used to form the extrudate. X-ray powder diffraction of the extrudate shows about 20% or less conversion of the MOF consolidated material into a phase differing from that of the pre-crystallized MOF powder material. | 2022-07-07 |
20220213126 | SMALL MOLECULE AUTOPHAGY INDUCERS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES - Disclosed herein are compounds and methods for treating cancer and neurodegenerative diseases. In some examples, the compounds increase autophagy. | 2022-07-07 |
20220213127 | EMITTING COMPOUND AND ORGANIC LIGHT EMITTING DEVICE INCLUDING THE SAME - An emitting compound of following and an organic light emitting device includes the flowing emitting compound. | 2022-07-07 |
20220213128 | L-Dopa Enhanced with a Neuroprotective Agent as a Therapy for Parkinson's Disease - Compounds and methods of using the compounds for the treatment of Parkinson's Disease are disclosed. The compound is created by the conjugation between L-Dopa and alpha lipoic acid. | 2022-07-07 |
20220213129 | SILICON OXIDE FILM, MATERIAL FOR GAS BARRIER FILM, AND METHOD FOR PRODUCING SILICON OXIDE FILM - To provide a silicon oxide film which exhibits high gas barrier performance even under a thin film condition. | 2022-07-07 |
20220213130 | HETEROCYCLIC GLP-1 AGONISTS - This disclosure relates to GLP-1 agonists of Formula (I): including pharmaceutically acceptable salts and solvates thereof, and pharmaceutical compositions including the same. | 2022-07-07 |
20220213131 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES - Provided are compounds having a ligand L | 2022-07-07 |
20220213132 | ORGANOMETALLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND DIAGNOSTIC COMPOSITION INCLUDING THE SAME - An organometallic compound represented by Formula 1: | 2022-07-07 |
20220213133 | Ferric Organic Compounds, Uses Thereof and Methods of Making Same - The present invention discloses a novel form of ferric organic compounds, including a form of ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. The ferric organic compounds of the present invention can be delivered effectively by oral route with better delivery to treat patients suffering from hyperphosphatemia, metabolic acidosis and other disorders responsive to ferric organic compound therapy. | 2022-07-07 |
20220213134 | METHOD FOR PRODUCING RNA - The present invention provides a method for preparing RNA by a phosphoramidite solid-phase synthesis using an porous inorganic carrier containing a primary amino group, the method being able to bring about an increased purity even in the synthesis of medium-stranded to long-stranded RNA. In the method for producing RNA, an amount of the primary amino group contained in the porous inorganic carrier satisfies the following formula (1): 0.7≤(I×R)/S≤1.8 [wherein, I is an amount of the amino group per unit mass of the porous inorganic carrier (μmol/g), as measured by a | 2022-07-07 |
20220213135 | DERIVATIVES OF GLYCERO-MANNO-HEPTOSE PHOSPHATE AND THEIR USE IN MODULATING AN IMMUNE RESPONSE - The disclosure provides compounds of formula (I), | 2022-07-07 |
20220213136 | NEW CATECHOLAMINE PRODRUGS FOR USE IN THE TREATMENT OF PARKINSON'S DISEASES - The present invention provides compounds of formula (Id) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease. | 2022-07-07 |
20220213137 | COMPOSITIONS AND METHODS FOR TREATING CNS DISORDERS - Described herein are neuroactive steroids of the Formula (I): | 2022-07-07 |
20220213138 | CYCLIC COMPOUNDS AND METHODS OF MAKING AND USING - Disclosed are compounds and methods for highly effective chemoselective peptide cyclization and bicyclization directly on unprotected peptides and other compounds as well as the compounds produced by the methods, which have a novel structural motif. The fast reaction rate and operational simplicity render this method to be highly effective to synthesize cyclic structures, i.e. cyclic peptides. The cyclic compounds allow for various functionalities useful in chemical biology study and drug discovery. | 2022-07-07 |
20220213139 | MANUFACTURE OF DISULFIDE BONDED PEPTIDES - A method and apparatus for the manufacture of disulfide bonded peptides is provided, wherein a solution of an oxidizing agent and a solution of a peptide comprising at least two sulfhydryl groups are added simultaneously into a reaction vessel under such conditions that the average concentration of the oxidizing agent inside the reaction vessel is essentially zero during simultaneous addition. | 2022-07-07 |
20220213140 | METHOD FOR PURIFYING FC REGION-MODIFIED ANTIBODY - The present inventors discovered affinity purification resins having sufficient binding affinity for Fc region variants with reduced binding to Protein A. Specifically, immunoglobulins containing an Fc region variant having reduced binding to Protein A could be purified using a Protein A-modified ligand containing a structure in which the amino acids of the C-domain have been substituted as an Fc ligand. | 2022-07-07 |
20220213141 | DYNAMICS WITHIN SUPRAMOLECUAR IKVAV MATRICES ENHANCE FUNCTIONAL MATURATION OF HUMAN IPSCS-DERIVED NEURONS AND REGENERATION - Provided herein are peptide amphiphiles (PAs) comprising a bioactive peptide, nanofibers displaying the bioactive PAs, and methods of use thereof. The disclosed peptide amphiphiles comprise a hydrophobic tail, a structural peptide segment, a charged peptide segment, and a bioactive IKVAV peptide. The disclosed PAs may be used in cell culture methods and in methods of treating central nervous system injury. | 2022-07-07 |
20220213142 | PEPTIDE COMPOUND AND APPLICATION THEREOF, AND COMPOSITION CONTAINING PEPTIDE COMPOUND - Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R. | 2022-07-07 |
20220213143 | METHOD OF TREATMENT - The present invention relates generally to the field of immunomodulation. Taught herein is an agent for inhibiting immunostimulation mediated by a Toll-like receptor useful in the treatment of viral and microbial pathogenesis, diseases involving elements of autoimmunity and inflammation as well as cancer. The agent antagonizes disulfide bond formation between C98 and C475 of Toll-like receptor 7 (TLR7) thereby preventing TLR7 activation. Pharmaceutical compositions are also enabled herein. | 2022-07-07 |
20220213144 | HALOGENATED ANTIMICROBIAL PEPTOIDS - A poly-N-substituted glycine compound of a formula | 2022-07-07 |
20220213145 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 - The present invention relates to polypeptides which are covalently bound to molecular scaffolds such that two or more peptide loops are subtended between attachment points to the scaffold. In particular, the invention describes peptides which are high affinity binders of CD137. The invention also includes drug conjugates comprising said peptides, conjugated to one or more effector and/or functional groups, to pharmaceutical compositions comprising said peptide ligands and drug conjugates and to the use of said peptide ligands and drug conjugates in preventing, suppressing or treating a disease or disorder mediated by CD137. | 2022-07-07 |
20220213146 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN - Provided herein is a platform technology for designing stabilized peptides that covalently bind their target protein and thereby inhibit the activity of the target protein. Also provided are exemplary stabilized peptides that can be used for covalent modification of their target proteins. | 2022-07-07 |
20220213147 | PURIFICATION OF VIRUS LIKE PARTICLES - Methods of purifying virus-like particles (VLPs) that are substantially free of process contaminants and infectious agents. The methods incorporate, for example, low-pH treatment during harvest and/or inactivation by a solvent and/or detergent during VLP capture. | 2022-07-07 |
20220213148 | MODIFIED S2 SUBUNIT OF THE CORONAVIRUS SPIKE PROTEIN - The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 865. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein. | 2022-07-07 |
20220213149 | ANTIGEN DELIVERY PLATFORMS - This disclosure provides platforms for delivery of herpes virus proteins to cells, particularly proteins that form complexes in vivo. In some embodiments these proteins and the complexes they form elicit potent neutralizing antibodies. Thus, presentation of herpes virus proteins using the disclosed platforms permits the generation of broad and potent immune responses useful for vaccine development. | 2022-07-07 |
20220213150 | METHODS OF DETECTION AND REMOVAL OF RHABDOVIRUSES FROM CELL LINES - The present disclosure relates to compositions, methods, mixtures, and kits for detecting the presence of, and for removing, a virus from a product produced in an insect cell. The disclosure also relates to proteins, peptides, polypeptides, drug substances, biological products, vaccine antigens, and virus-like particles that are produced in an insect cell and that are free or substantially free of a virus. The disclosure also relates to compositions, methods, assays, and kits for detecting a rhabdovirus in a sample. | 2022-07-07 |
20220213151 | COMPOSITIONS AND METHODS FOR TREATMENT OF DISTENTABLE TISSUES - Provided herein are compositions and methods for treating cancer in a distentable tissue, for example, a bladder, a uterus, peritoneum, omentum, or eye. Useful compositions include DT-EGF fusion proteins as described herein. | 2022-07-07 |
20220213152 | ?-GLUCAN-BINDING PROTEIN, ?-GLUCAN DETECTION KIT, ARTIFICIAL DNA, AND BACTERIUM - The β-glucan-binding protein contains an amino acid sequence represented by SEQ ID NO: 1. | 2022-07-07 |
20220213153 | WORMS Scaffolds: Multi-scale protein complexes - The disclosure provides polypeptides as descried herein that including an amino acid sequence at least 50% identical to the amino acid sequence selected from the group consisting of SEQ ID NOS:1-46, oligomers of such polypeptides, methods for using such polypeptides and oligomers, and methods for designing such polypeptides and oligomers. | 2022-07-07 |
20220213154 | AGENTS MODULATING BETA-CATENIN FUNCTIONS AND METHODS THEREOF - Among other things, the present disclosure provides technologies for modulating functions of beta-catenin. In some embodiments, the present disclosure provides stapled peptides that interact with beta-catenin. In some embodiments, provided stapled peptides interact with beta-catenin at an Axin-binding site of beta-catenin. In some embodiments, the present disclosure provides compounds, compositions and methods for preventing and/or treating conditions, disorders and diseases that are associated with beta-catenin. | 2022-07-07 |
20220213155 | PROGRANULIN VARIANTS - Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein. | 2022-07-07 |
20220213156 | Peptides for use in therapy or prophylaxis of Herpesviridae-infections - The present invention relates to new peptides the amino acid sequences of which are derived from HD-5, for use in the treatment and/or prevention of Herpesviridae infections, in particular for treating and/or preventing a Betaherpesviridae infection, such as a HCMV-infection. | 2022-07-07 |
20220213157 | ELECTRICAL CONDUCTORS AND METHODS OF CONDUCTING IONS USING CALSEQUESTRIN PROTEINS - An in vitro electrical conductor is provided. The in vitro electrical conductor may include a plurality of Calsequestrin (CSQ) protein molecules. The CSQ protein molecules may be connected to form a tendril, a network structure, or a biological tunnel structure. An electrical device including the in vitro electrical conductor is provided. An ionic transistor including the in vitro electrical conductor is provided. An in vitro method of conducting ions from an ion source to an ion sink is further provided. The method may include providing an electrical conductor including a plurality of CSQ protein molecules and conducting ions through the electrical conductor to the ion sink. The CSQ protein molecules may be connected to form a tendril, a network structure, or a biological tunnel structure. | 2022-07-07 |
20220213158 | CHIMERIC PROTEINS FOR TARGETING dsRNA - Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein. | 2022-07-07 |
20220213159 | NOVEL CANCER ANTIGENS AND METHODS - There are disclosed inter alia polypeptides and nucleic acids encoding said polypeptides which are useful in the treatment, prevention and diagnosis of cancer, particularly melanoma, especially cutaneous melanoma and uveal melanoma. | 2022-07-07 |
20220213160 | PROTEIN HETERODIMER AND USE THEREOF - The present application provides a protein heterodimer and use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL12a, and the second polypeptide chain comprises IL12b. The protein heterodimer also comprises IL2 or its functional fragments, GMCSF or its functional fragments, and one or more targeting moieties. The protein heterodimer can be used for the treatment of tumors. | 2022-07-07 |
20220213161 | MODIFIED INTERLEUKIN 12 AND USE THEREOF IN PREPARING DRUGS FOR TREATING TUMOURS - The present invention discloses a modified interleukin 12 (nsIL-12) and its gene, recombinant vector and use in manufacture of a medicament for treatment of tumors. When the oncolytic adenovirus vector carrying the modified interleukin 12 gene targets tumor tissue, the modified interleukin 12 is continuously expressed at a low level and mainly distributed in the local tumor tissue, which improves the specificity to tumor cells and reduces the systemic toxicity of interleukin 12; the modified interleukin 12 shows stronger inhibitory effect on tumor growth in intraperitoneally disseminated tumors and orthotopic tumors, and has low toxicity. The modified interleukin 12 armed oncolytic viruses show excellent antitumor effects, with a significant regression of tumors and lower toxicity compared with the existing IL-12 armed virus. | 2022-07-07 |
20220213162 | ENGINEERED IL-2 Fc FUSION PROTEINS - The present invention provides IL-2-Fc fusion proteins comprising IL-2 variants. | 2022-07-07 |
20220213163 | IL-2 CHIMERIC PROTEINS FOR IMMUNOSUPPRESSION - Methods of increasing regulatory T cells in a subject by administering an IL-2 chimeric molecule with increased serum half-life as compared to wild-type Il-2 are provided. Methods of treating inflammatory and autoimmune disease are also provided. | 2022-07-07 |
20220213164 | TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST - A triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed. | 2022-07-07 |
20220213165 | THERAPEUTIC PEPTIDES - Provided herein are therapeutic peptides. In some aspects, therapeutic peptides are provided that can alter EphB4/EFNB2 signaling and can be used to treat a cancer. In some embodiments, the peptides are comprised in nanoparticles, such as core-cross-linked polymeric micelles (CCPM). | 2022-07-07 |
20220213166 | METHODS OF TREATING CANCER - Provided are methods of treating cancer (e.g., non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), HER2-positive gastric/gastroesophageal junction (GEJ) cancer, de novo or transformed diffuse large B cell lymphoma (DLBCL), or indolent lymphoma) in an individual that comprise administering to the individual (a) a polypeptide comprising a SIRPα D1 domain variant and an Fc domain variant, and (b) an anti-cancer antibody (e.g., an anti-PD1 antibody, anti-HER2 antibody, or an anti-CD20 antibody). Also provided are related kits pharmaceutical compositions. | 2022-07-07 |
20220213167 | ENGINEERED CELLS EXPRESSING ANTI-TUMOR T CELL RECEPTORS AND METHODS OF USE THEREOF - Provided herein are compositions comprising recombinant mammalian cells that express recombinant T cell receptors with specificity against gp100 peptide:MHC antigens. Also provided are therapeutic methods of using the recombinant mammalian cells as cell therapies against melanoma tumors. | 2022-07-07 |
20220213168 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS - A method of treating a patient who has hepatocellular carcinoma (HCC), colorectal carcinoma (CRC), glioblastoma (GB), gastric cancer (GC), esophageal cancer, NSCLC, pancreatic cancer (PC), renal cell carcinoma (RCC), benign prostate hyperplasia (BPH), prostate cancer (PCA), ovarian cancer (OC), melanoma, breast cancer (BRCA), CLL, Merkel cell carcinoma (MCC), SCLC, Non-Hodgkin lymphoma (NHL), AML, gallbladder cancer and cholangiocarcinoma (GBC, CCC), urinary bladder cancer (UBC), and uterine cancer (UEC) includes administering to said patient a composition containing a population of activated T cells that selectively recognize cells in the patient that aberrantly express a peptide. A pharmaceutical composition contains activated T cells that selectively recognize cells in a patient that aberrantly express a peptide, and a pharmaceutically acceptable carrier, in which the T cells bind to the peptide in a complex with an MHC class I molecule, and the composition is for treating the patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. A method of treating a patient who has HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC includes administering to said patient a composition comprising a peptide in the form of a pharmaceutically acceptable salt, thereby inducing a T-cell response to the HCC, CRC, GB, GC, esophageal cancer, NSCLC, PC, RCC, BPH, PCA, OC, melanoma, BRCA, CLL, MCC, SCLC, NHL, AML, GBC, CCC, UBC, and/or UEC. | 2022-07-07 |